Company news
Q32 Bio Inc. news in 2021
Q32 Bio Inc.'s news releases, calls and decks from 2021, newest first.
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
November 14, 2021
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
October 20, 2021
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
October 19, 2021
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
October 17, 2021
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
October 11, 2021
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
August 11, 2021
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
August 4, 2021
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
May 12, 2021
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
May 5, 2021
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
May 2, 2021
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model
April 27, 2021
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
April 13, 2021
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
April 11, 2021
Homology Medicines Announces Pricing of Public Offering of Common Stock
April 6, 2021
Homology Medicines Announces Proposed Public Offering of Common Stock
April 5, 2021
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 10, 2021
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
February 28, 2021
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
February 24, 2021
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
February 7, 2021
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
January 5, 2021